Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Purpose: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the correlation of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 with other clinical features. Experimental Design: We investigated the clinical impact of gene expression profiling (GEP)–derived expression levels of NR3C1 in 351 patients with GEP data available at baseline and in 130 with data available at relapse, among 668 subjects accrued to Total Therapy 2 (TT2). The effect of the expression of NR3C1 at baseline (previously published under GSE2685) and at relapse was analyzed in the context of treatment (thalidomide vs. no thalidomide) and other clinical parameters.

研究目的：地塞米松仍是多发性骨髓瘤治疗的核心用药，本研究旨在探讨糖皮质激素受体基因NR3C1的基线与复发时表达水平与其他临床特征的相关性。
实验设计：本研究针对纳入Total Therapy 2（TT2）临床试验的668名受试者，分析其中351名具备基线基因表达谱（Gene Expression Profiling, GEP）数据、130名具备复发时GEP数据的患者的NR3C1基因表达水平的临床影响。并结合治疗方案（沙利度胺vs. 非沙利度胺治疗）及其他临床参数，对基线（此前已发表于GSE2685数据集）与复发时的NR3C1基因表达效应进行了分析。